Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios-Athanasios Dimopoulos

Showing results (181-190 of 283) with videos related to

Pageof 29
Sort By:
Microorganisms|July 27, 2024
Necrotizing Laryngitis in Patients with Hematologic Disease: The First Case-Report Due to PDR <i>Acinetobacter baumannii</i> and Literature ReviewIoanna Tatouli, Nikolaos Dedes, Andreas Bozikas, et al.
British Journal of Cancer|May 4, 2026
Delving into tRNA-derived small RNAs in multiple myeloma: elevated 3'U-tRF<sup>SerTGA</sup> leads to poor disease prognosisKonstantinos Soureas, Panagiotis Malandrakis, Maria-Alexandra Papadimitriou, et al.
BMC Cancer|March 6, 2014
The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinomaAnastasios Stofas, Georgia Levidou, Christina Piperi, et al.
Viruses|December 30, 2020
Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 InfectionNikolaos Orologas-Stavrou, Marianna Politou, Pantelis Rousakis, et al.
The Oncologist|June 9, 2017
Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical EvaluationAristotle Bamias, Bernard Escudier, Cora N Sternberg, et al.
Haematologica|March 20, 2025
Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trialSalomon Manier, Meletios-Athanasios Dimopoulos, Xavier P Leleu, et al.
Frontiers in Immunology|December 13, 2021
Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 InfectionMargherita Rosati, Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, et al.
Cancers|August 7, 2021
A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple MyelomaAristea-Maria Papanota, Panagiotis Tsiakanikas, Christos K Kontos, et al.
Nutrients|February 13, 2025
Possible Prognostic Role of BMI Before Chemotherapy in the Outcomes of Women with Ovarian CancerStavroula A Paschou, Angeliki Andrikopoulou, Nikoletta Mili, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
<i>BRCA1/2</i> Mutation Types Do Not Affect Prognosis in Ovarian Cancer PatientsMichalis Liontos, Eleni Zografos, Panagiotis Zoumpourlis, et al.
Pageof 29

Showing results (181-190 of 283) with videos related to

Sort By:
Pageof 29
Microorganisms|July 27, 2024
Necrotizing Laryngitis in Patients with Hematologic Disease: The First Case-Report Due to PDR <i>Acinetobacter baumannii</i> and Literature ReviewIoanna Tatouli, Nikolaos Dedes, Andreas Bozikas, et al.
British Journal of Cancer|May 4, 2026
Delving into tRNA-derived small RNAs in multiple myeloma: elevated 3'U-tRF<sup>SerTGA</sup> leads to poor disease prognosisKonstantinos Soureas, Panagiotis Malandrakis, Maria-Alexandra Papadimitriou, et al.
BMC Cancer|March 6, 2014
The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinomaAnastasios Stofas, Georgia Levidou, Christina Piperi, et al.
Viruses|December 30, 2020
Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 InfectionNikolaos Orologas-Stavrou, Marianna Politou, Pantelis Rousakis, et al.
The Oncologist|June 9, 2017
Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical EvaluationAristotle Bamias, Bernard Escudier, Cora N Sternberg, et al.
Haematologica|March 20, 2025
Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trialSalomon Manier, Meletios-Athanasios Dimopoulos, Xavier P Leleu, et al.
Frontiers in Immunology|December 13, 2021
Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 InfectionMargherita Rosati, Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, et al.
Cancers|August 7, 2021
A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple MyelomaAristea-Maria Papanota, Panagiotis Tsiakanikas, Christos K Kontos, et al.
Nutrients|February 13, 2025
Possible Prognostic Role of BMI Before Chemotherapy in the Outcomes of Women with Ovarian CancerStavroula A Paschou, Angeliki Andrikopoulou, Nikoletta Mili, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
<i>BRCA1/2</i> Mutation Types Do Not Affect Prognosis in Ovarian Cancer PatientsMichalis Liontos, Eleni Zografos, Panagiotis Zoumpourlis, et al.
Pageof 29